8 research outputs found
A formal approach to autonomic systems programming: the SCEL Language
Get PDFThe autonomic computing paradigm has been proposed to cope with size, complexity and dynamism of contemporary
software-intensive systems. The challenge for language designers is to devise appropriate abstractions
and linguistic primitives to deal with the large dimension of systems, and with their need to
adapt to the changes of the working environment and to the evolving requirements. We propose a set of
programming abstractions that permit to represent behaviors, knowledge and aggregations according to
specific policies, and to support programming context-awareness, self-awareness and adaptation. Based on
these abstractions, we define SCEL (Software Component Ensemble Language), a kernel language whose
solid semantic foundations lay also the basis for formal reasoning on autonomic systems behavior. To show
expressiveness and effectiveness of SCEL’s design, we present a Java implementation of the proposed abstractions
and show how it can be exploited for programming a robotics scenario that is used as a running
example for describing features and potentials of our approac
A formal approach to autonomic systems programming: the SCEL language
No full textSoftware-intensive cyber-physical systems have to deal with massive numbers of components, featuring complex interactions among components and with humans and other systems. Often, they are designed to operate in open and non-deterministic environments, and to dynamically adapt to new requirements, technologies and external conditions. This class of systems has been named ensembles and new engineering techniques are needed to address the challenges of developing, integrating, and deploying them. In the paper, we briefly introduce SCEL (Software Component Ensemble Language), a kernel language that takes a holistic approach to programming autonomic computing systems and aims at providing programmers with a complete set of linguistic abstractions for programming the behavior of autonomic components and the formation of autonomic components ensembles, and for controlling the interaction among different components
MEDICAL SCIENCE. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction
No full textA multicentre, randomised, open trial with a 2 x 2 factorial design was conducted to compare the benefits and risks of two thrombolytic agents, streptokinase (SK, 1\ub75 MU infused intravenously over 30-60 min) and alteplase (tPA, 100 mg infused intravenously over 3 h) in patients with acute myocardial infarction admitted to coronary care units within 6 h from onset of symptoms. The patients were also randomised to receive heparin (12 500 U subcutaneously twice daily until discharge from hospital, starting 12 h after beginning the tPA or SK infusion) or usual therapy. All patients without specific contraindications were given atenolol (5-10 mg iv) and aspirin (300-325 mg a day). The end-point of the study was the combined estimate of death plus severe left ventricular damage. 12 490 patients were randomised to four treatment groups (SK alone, SK plus heparin, tPA alone, tPA plus heparin). No specific differences between the two thrombolytic agents were detected as regards the combined end-point (tPA 23\ub71%; SK 22\ub75%; relative risk 1\ub704, 95% Cl 0\ub795-1\ub713), nor after the addition of heparin to the aspirin treatment (hep 22\ub77%, no hep 22\ub79%; RR 0\ub799, 95% Cl 0\ub791-1\ub708). The outcome of patients allocated to the four treatment groups was similar with respect to baseline risk factors such as age, Killip class, hours from onset of symptoms, and site and type of infarct. The rates of major in-hospital cardiac complications (reinfarction, post-infarction angina) were also similar. The incidence of major bleeds was significantly higher in SK and heparin treated patients (respectively, tPA 0\ub75%, SK 1\ub70%, RR 0\ub757, 95% Cl 0\ub738-0\ub785; hep 1\ub70%, no hep 0\ub76%, RR 1\ub764, 95% Cl 1\ub709-2\ub745), whereas the overall incidence of stroke was similar in all groups. SK and tPA appear equally effective and safe for use in routine conditions of care, in all infarct patients who have no contraindications, with or without post-thrombolytic heparin treatment. The 8\ub78% hospital mortality of the study population (compared with approximately 13% in the control cohort of the GISSI-1 trial) indicates the beneficial impact of the proven acute treatments for AMI. \ua9 1990
